

Subject Index

A

- Acoustic neuroma
 - epidemiological evidence of allergic disorders and cancer occurrence, 62–63
 - See also* Brain tumors; Neuroblastoma
- Activation-induced deaminase (AID)
 - in CSR, 15–18
 - replication protein A (RPA) binding to, 18
- Acute leukemia
 - acute lymphoblastic leukemia (ALL), 83, 126–127
 - acute myelogenous leukemia (AML), 83
 - See also* Chronic leukemia
- Adenocarcinoma
 - mast cells in, 145
 - See also* Angiogenesis
- Affinity maturation, 42–43
 - in germinal centers (GC), 37–38
 - See also* High-affinity IgE antibodies
- Airway tissue remodeling
 - airway smooth muscle (ASM) function, 142–143
 - mast cells and, 142–143
- Allergen-associated molecular patterns (AAMP), 238–242
 - See also* Pathogen-associated molecular patterns (PAMPs); Tumor-associated molecular patterns
- AllergoOncology
 - definition, 8
 - history, 4–8
 - IgE historical aspects and, 6–8
 - See also* Allergy; IgE in cancer therapy
- AllergoOncology (epidemiological evidence of allergic disorders and cancer occurrence), 47
 - methods, 48
 - results, 48–52
 - bladder cancer, 67
 - bone cancer, 68
 - colorectal cancer, 64–65
 - esophageal cancer, 67
 - lung cancer, 52–56
 - pancreatic cancer, 56–60
 - reproductive cancers, 65–66
 - skin cancer, 68
 - stomach cancer, 67
 - tumors of brain and nervous system, 60–64
- AllergoOncology (epidemiological evidence of allergic disorders and hematopoietic malignancies), 79–122
 - cancers immunoregulatory mechanism, 81
 - cancers incidence and incidence rates, 80
 - case–control studies, 81
 - cohort studies, 81
 - HL, 114–115
 - NHL, 98–111
 - Hodgkin lymphoma (HL), 112–115
 - leukemias, 82–96
 - methods of review, 81–82
 - non-Hodgkin lymphoma (NHL), 96–112
 - plasma cell malignancies, 113, 116–122
 - potential mechanistic interactions between allergy/atopy associated with hematopoietic cancers development, 122
 - CD23 expression stabilization by IgE, 124–126
 - IgE/allergy-mediated enhancement of antitumor immunity, 123–124
 - IgE-mediated allergies and B-cell NHL, 126–128

Allergy

- cancer and, *see* AllergoOncology
- definition, 4
- history, 2–3
- mast cells in, 137–143
- Pirquet's allergy, 3

Anaphylaxis

- anti-tumor, 166–167
- IgE and anaphylactic reaction, 231–232

Angiogenesis

- mast cells in cancer, 143–144
- See also* AllergoOncology

Antibodies generation

- high-affinity, 37–44
 - generation pathways, 41–44
 - sequential switching to IgE in mice and humans, 40
- low-affinity, 37–39
 - class switching, 39
 - direct switching from IgM to IgE, 38
- See also* Immunoglobulins (Ig)

Antibody-dependent cell-mediated cytotoxicity (ADCC)

- IgE, 164
- IgG, 163
- MOv18 IgE-mediated, 197–199
- See also* IgE in cancer therapy

Antibody-dependent cell-mediated phagocytosis (ADCP), 164

- MOv18 IgE-mediated, 199–202
- trastuzumab-like IgE-mediated, 202

Antibody-secreting plasma, 26**Antigen-presenting cells (APC)**

- IgE
 - cancer therapy, 164–165
 - effector cells in cancer and, 193–194
 - mast cells as, 141–142
- See also* Crosslinking (antigens)

Anti-tumor

- anaphylaxis, 166–167
- IgE-mediated anti-tumor responses
 - IgE effector cell responses, 185–206
 - mouse IgE-induced tumor protection, 217–218
- immunity
 - IgE/allergy-mediated enhancement of antitumor immunity (hematopoietic malignancies), 123–124
 - Th2-mediated anti-tumor immunity, 255–268
- See also* IgE adjuvant effect (tumor vaccination); IgE in cancer therapy

Asthma

- acoustic neuroma and, 62–63
 - basal cell carcinoma, 67
 - bladder cancer, 67
 - brain tumor, 63
 - glioma, 60–61
 - meningioma and, 60–62
 - colorectal cancer, 64–65
 - esophageal cancer, 67
 - leukemia and
 - ALL, 83
 - AML, 83
 - CML, 83
 - lung cancer, 52–53, 55–56
 - multiple myeloma, 116
 - neuroblastoma and, 64
 - pancreatic cancer, 56–60
 - reproductive cancers, 65–66
 - stomach cancer, 67
 - urothelial cancer, 67
 - See also* Eczema; Hay fever
- Atopic dermatitis, 68**
- See also* Melanoma

B**B cell interactions**

- B-cell NHL, 96–97, 112, 126
- high-affinity IgE antibodies generation
 - IgE⁺ cells found outside GC in both T/B monoclonal and wild-type mice (experimental evidence), 42
 - T-B cells interaction, 37–38
- low-affinity IgE antibodies generation and B cells interaction, 38
 - direct switching aspects, 38–39
- Th2-mediated and anti-tumor immunity, 266
- See also* T cell interactions

B cell receptor (BCR), 22**Basal cell carcinoma**

- asthma and, 67
- See also* AllergoOncology

Basophils

- IgE effector cells in cancer and, 190
- IgE-mediated effector cell responses (experimental evidence), 203–204

Bladder cancer

- epidemiological evidence of allergic disorders and cancer occurrence, 67
- See also* AllergoOncology

Blood cancer, *see* AllergoOncology

- (epidemiological evidence of allergic disorders and hematopoietic malignancies)

- Bone cancer, 68
- Brain tumors
epidemiological evidence of allergic disorders and cancer occurrence, 60–63
See also Glioma; Meningioma
- Breast cancer
epidemiological evidence of allergic disorders and cancer occurrence, 65–66
mast cells in, 145
- C**
- Cancers
allergy and, *see* AllergoOncology
epidemiological evidence of allergic disorders and cancer occurrence, 52–68
hematopoietic malignancies, 79–122
IgE in cancer therapy, *see* IgE in cancer therapy
IgG in cancer therapy, 164, 168
IgE advantages over IgG, 162–165
Th2-mediated anti-tumor immunity, 265–266
See also Anti-tumor
- CD20 antibody
IgE (chimeric IgE targeting human CD20), 174–175
IgG, 174
- CD23 antibody
expression stabilization by IgE (hematopoietic malignancies), 124–126
IgE adjuvanticity in tumor vaccination (FcεRII), 223–225
IgE-mediated anti-tumor responses (pancreatic cancer case), 205
low affinity IgE receptor (FcεRII), 188
membrane-bound form (mCD23), 20–22
negative feedback function, IgE expression influence by, 20–22
soluble form (sCD23), 20–22
- CD4⁺ T cells
Th1 and Th2 paradigm in tumor biology, 256–257
See also Th2-mediated anti-tumor immunity
- CD8 antibody
CD8⁺ T cells (Tc2 cells), 267–268
rat/human chimeric IgE specific for murine, 169–170
- Cervical cancer (epidemiological evidence of allergic disorders and cancer occurrence), 66
- Chemokines
migratory plasmablasts and, 27
chemokine ligand (CXCL), 27
chemokine receptor (CXCR)
See also B cell interactions
- Chimeric ovarian carcinoma antigen-specific MOv18
in IgE-mediated anti-tumoral responses, 195
See also Effector cell responses
- Chronic leukemia
lymphocytic leukemia (CLL), 96
myelogenous leukemia (CML), 83
See also Acute leukemia
- Class switch recombination (CSR)
activation-induced deaminase (AID) in, 15–18
cytokine signaling and, 15
germline transcription (GLT) and, 16–18
interleukins and
IL-4, 15, 17
IL-6/10/21, 18
reduced class switch frequency to IgE locus, 14–18
- Class switching to IgE, 39
- Cleavage-polyadenylation specificity factor (CPSF), 25
- CNS tumors, *see* Nervous system tumors
- Colorectal cancer
epidemiological evidence of allergic disorders and cancer occurrence, 64–65
mast cells in, 145
murine and mouse/human chimeric IgE specific for antigenic determinant on carcinoma cells surface, 170–171
- Connective tissue mast cells (CTMC), 138–139
See also Mucosal mast cells (MMC)
- Contact hypersensitivity (CHS), 139
- Crosslinking (antigens)
IgE synthesis aspects, 235–238
immunoregulation aspects, 232–234
See also Allergen-associated molecular patterns (AAMP); Tumor-associated molecular patterns

- Cytokines
 class switch recombination (CSR)
 and, 15
 Th2 cytokines and anti-tumor immunity,
 257–260
See also Interleukins (IL)
- Cytoplasmic domain (mIgE), 22
- D**
- Dendritic cells (DCs)
 mast cells and, 139–141
- Dermatitis
 atopic, 68
See also Eczema
- E**
- Eczema
 cancer and
 acoustic neuroma, 61–63
 glioma, 60–61
 lung cancer, 55–56
 meningioma, 60–62
 neuroblastoma, 64
 pancreatic cancer, 58–59
 skin cancer and, 68
See also Asthma; Hay fever
- Effector cell responses
 IgE effector cells in cancer
 antigen-presenting cells,
 193–194
 basophils, 190
 eosinophils, 192–193
 macrophages, 191–192
 mast cells, 190
 missing activation signals and tumor
 growth, 189–194
 monocytes, 191–192
 natural killer cells, 193
- IgE–FcεRI complex, 186–188
- IgE–FcεRII complex, 188
- IgE-mediated anti-tumor responses
 chimeric ovarian carcinoma
 antigen-specific MOv18 IgE
 effector cells, 195
 MOv18, 195–202
 pancreatic cancer case (CD23), 205
 PBMC and monocyte activities, 194
 stimulation of mast cells, basophils
 and eosinophils (experimental
 evidence), 203–204
 trastuzumab like IgE, 202–203
 MOv18 IgE-mediated responses, 196
 chimeric ovarian carcinoma, 195
 tumor killing mechanisms (ADCC),
 197–199
 tumor killing mechanisms (ADCP),
 199–202
- Endometrial cancer (epidemiological evidence
 of allergic disorders and cancer
 occurrence), 66
- Eosinophils
 IgE effector cells
 in cancer, 192, 193
 responses (experimental evidence),
 203–204
 Th2-mediated anti-tumor immunity,
 262–264
- Epidemiological evidence
 allergic disorders and cancer occurrence,
see AllergoOncology
 (epidemiological evidence of
 allergic disorders and cancer
 occurrence)
 hematopoietic malignancies, *see*
 AllergoOncology (epidemiological
 evidence of allergic disorders and
 hematopoietic malignancies)
- Epsilon-binding protein (e-BP)
 galectin-3, 189
See also Fc epsilon (Fcε) receptors
- Epsilon-HC gene, 26
See also Polyadenylation
- Esophageal cancer
 cigarette smoking and, 67
 epidemiological evidence of allergic
 disorders and cancer
 occurrence, 67
- Extracellular membrane-proximal domain
 (EMPD)
 mIgE, 22
- F**
- Fc epsilon (Fcε) receptors
 adjuvanticity in tumor vaccination
 FcεRI humanized mice and human IgE
 in tumor vaccination, 225–226
 IgE–FcεRI complex, 223–224
 IgE–FcεRII complex, 118–119
 high affinity (FcεRI), 185–186
 low affinity (FcεRII), 188
See also Galectin-3
- Folate binding protein
 mouse/human chimeric IgE specific for
 human folate binding protein,
 171–173
See also IgE in cancer therapy

G

- Galectin-3
tumor cell death and, 189
See also Fc epsilon (F ϵ) receptors
- Genital cancer
epidemiological evidence of allergic disorders and cancer occurrence, 66
See also Reproductive cancers
- Germinal centers (GC)
affinity maturation and, 37–38
IgE⁺ cells found outside GC in both T/B monoclonal mice and wild-type mice
high-affinity IgE antibodies generation (experimental evidence), 42
See also High-affinity IgE antibodies
- Germline transcription (GLT), 16–18
- Glioma
epidemiological evidence of allergic disorders and cancer occurrence, 60–61
See also Brain tumors
- Glycoprotein 36 (gp36)
MMTV, 168–169
See also IgE in cancer therapy

H

- Hay fever
cancer and
acoustic neuroma, 62–63
acute lymphoblastic leukemia (ALL), 83
brain tumor, 63
colorectal cancer, 64–65
glioma, 60–61
lung cancer, 55–56
meningioma, 60, 62
neuroblastoma, 64
pancreatic cancer, 57–59
reproductive cancers, 65–66
See also Asthma
- Heavy chain (HC) locus
 ϵ -HC gene, 14, 26
 γ -1 (γ 1)-HC, 14
reduced class switch frequency to IgE locus, 14
- Hematopoietic malignancies,
see AllergoOncology (epidemiological evidence of allergic disorders and hematopoietic malignancies)

- HER2/neu
anti-HER2/neu IgE response, 175
engineered IgE specific for human, 173–174
- High-affinity Fc epsilon (F ϵ) receptors
Fc ϵ RI (IgE-Fc ϵ RI complex), 185
adjuvanticity in tumor vaccination, 218–219
Fc ϵ RI humanized mice and human IgE in tumor vaccination, 225–226
See also Low-affinity Fc epsilon (F ϵ) receptors
- High-affinity IgE antibodies, 37–38
generation pathways
IgE antibodies undergoing somatic hypermutation and affinity maturation, 42–43
IgE⁺ cells found outside germinal centers in both T/B monoclonal mice and wild-type mice, 42
IgG1⁺ B cells generating IgE antibodies by sequential switching, 43
interleukin-21 inhibiting sequential switching of IgG1⁺ cells to IgE, 43–44
sequential switching to IgE in mice and humans, 40
summary of findings, 41
somatic hypermutation (SHM), 37
T–B cell interactions, 37–38
versus low-affinity IgE antibodies, 37–38
See also Low-affinity IgE antibodies
- Hodgkin lymphoma (HL)
allergic disorders and epidemiological evidence of, 112–115
case–control studies, 114–115
mast cells in, 145
See also Non-Hodgkin lymphoma (NHL)
- HS1-associated protein X-1 (HAX-1), 24
- Human IgE
chimeric IgE
specific for antigenic determinant on colorectal carcinoma cells surface, 170–171
specific for human folate binding protein, 171–173
specific for murine CD8, 169–170
targeting human CD20, 174–175
Fc ϵ RI humanized mice and human IgE in tumor vaccination, 225–226
MVA as resource for human therapy and recombinant protein expression, 221

Human IgE (*cont.*)
 transgenic mice use for IgE receptor involvement and human IgE implementation, 222
See also Mouse IgE

Human tumors
 mast cells in cancer, 145–147
See also Cancers

Humoral immunological memory, 26
See also Plasmablasts

Hypermutation
 somatic (SHM), 37
See also High-affinity IgE antibodies

I

IgE, 160
 adjuvant effect, *see* IgE adjuvant effect (tumor vaccination)
 AllergoOncology history and, 4–8
 anaphylactic reaction and, 231–232
 antibodies generation
 high-affinity, 37–44
 low-affinity, 37–39
 cancer therapy, *see* IgE in cancer therapy
 crosslinking (antigens)
 IgE synthesis aspects, 235–238
 immunoregulation aspects, 232–234

IgE-FcεRI complex
 adjuvant activity in tumor vaccination, 223–224
 effector cell responses, 185–188

IgE-FcεRII complex
 adjuvant activity in tumor vaccination, 218–219
 effector cell responses, 188

hematopoietic malignancies and
 CD23 expression stabilization by IgE, 124–126
 IgE/allergy-mediated enhancement of antitumor immunity, 123–124
 IgE-mediated allergies and B-cell NHL, 126–128

identification (1967), 4

membrane, *see* Membrane IgE (mIgE)

molecular mechanisms, 13–28
 CD23 negative feedback function, 20–22
 Ig mRNA processing, 24–26
 IgE plasmablasts contribution to
 long-lived plasma cell pool, 26–27
 impaired splicing and polyadenylation restricting mature mIgE transcript generation, 24–26

mIgE antigen receptor function and *in vivo* IgE synthesis, 22–24
 reduced CSR to IgE locus, 14–18
 serum IgE half life, 18–20

receptors
 high-affinity (FcεRI), 185–188, 223
 low-affinity (FcεRII), 188, 222
 structure and binding properties, 161–162

targets
 AAMP, 238–242
 TAMP, 242, 244
See also Human IgE; Mouse IgE

IgE adjuvant effect (tumor vaccination), 215

IgE-FcεRI adjuvant activity
 FcεRI humanized mice and human IgE, 225–226
 in tumor vaccination, 223–224

mouse IgE-induced tumor protection, 218–226
 transgenic mice use for IgE receptor involvement and human IgE implementation, 222
 Vaccinia virus and MVA as cell killing agents coupled to IgE loading, 220–221

mouse membrane-bound IgE
 implementation by recombinant MVA, 224–225

IgE in cancer therapy, 159
 function and relevance in cancer therapy, 162–165

IgE effector cells, *see* Effector cell responses

local anti-tumor anaphylaxis, 166–167

passive cancer immunotherapy (using tumor-specific IgE)
 chimeric IgE targeting human CD20, 174–175
 engineered IgE specific for human HER2/neu, 173–174
 mouse/human chimeric IgE specific for human folate binding protein, 171–173
 murine and mouse/human chimeric IgE specific for antigenic determinant on colorectal carcinoma cells surface, 170–171
 murine IgE specific for gp36 of MMTV, 168–169
 rat/human chimeric IgE specific for murine CD8, 169–170

Th2-mediated and anti-tumor immunity, 265–266

- tumor-specific monoclonal IgE generation
 - endogenous IgE response via mimotope vaccination, induction of, 175–176
 - monoclonal and recombinant IgE development, 167–168
 - tumor-specific IgE for passive cancer immunotherapy, 168–175
 - See also* Fc epsilon (Fcε) receptors; Galectin-3; IgE adjuvant effect (tumor vaccination)
 - IgG, 14, 160
 - high-affinity IgE antibodies generation
 - aspects (sequential switching to IgE in mice and humans), 40
 - IL-21 inhibiting switching of IgG1⁺ to IgE, 43–44
 - IgG1⁺ B cells generating IgE, 43
 - Ig mRNA processing, 25
 - in cancer therapy, 164, 168
 - advantages of IgE therapy over IgG, 162–165
 - Omalizumab therapy, 162–163
 - Th2-mediated anti-tumor immunity, 265–266
 - serum, 19–20
 - See also* IgE; Trastuzumab-like IgE
 - Immunoglobulins (Ig), 159–160
 - A (IgA), 25, 160
 - D (IgD), 160
 - E, *see* IgE
 - G, *see* IgG
 - M (IgM), 160
 - high-affinity IgE antibodies generation
 - aspects (sequential switching to IgE in mice and humans), 40
 - Ig mRNA processing, 25
 - low-affinity IgE antibodies generation
 - aspects (direct switching from IgM to IgE), 38–39
 - mRNA processing
 - membrane form, 24–26
 - secreted form, 24–26
 - serum
 - IgE, 18–20
 - IgG, 19–20
 - Y (IgY), 13
 - See also*
 - Interleukins (IL)
 - class switch recombination (CSR) and
 - IL-4, 15, 17
 - IL-6/10/21, 18
 - IL-21 inhibiting sequential switching of IgG1⁺ cells to IgE (high-affinity IgE antibodies generation), 43–44
 - Th2 cytokines and anti-tumor immunity
 - IL-13, 258, 260
 - IL-24, 258, 261
 - IL-25, 258, 261–262
 - IL-4, 257–260
- L**
- Leukemias
 - acute, 83
 - ALL, 83, 126–127
 - AML, 83
 - allergic disorders and epidemiological evidence of, 84–96
 - case–control, 86–95
 - cohort studies, 84–85
 - chronic
 - CLL, 96
 - CML, 83
 - lymphocytic, 83
 - myelogenous, 83
 - See also* AllergoOncology (epidemiological evidence of allergic disorders and hematopoietic malignancies)
 - Low-affinity Fc epsilon (Fcε) receptors
 - adjuvanticity in tumor vaccination (IgE-FcεRI complex), 223–224
 - FcεRII (CD23), 188
 - See also* CD23 antibody; High-affinity Fc epsilon (Fcε) receptors
 - Low-affinity IgE antibodies
 - B cells interactions and, 38
 - generation
 - class switching, 39
 - direct switching from IgM to IgE, 38
 - versus high-affinity IgE antibodies, 37–38
 - See also* High-affinity IgE antibodies
 - Lung cancer
 - epidemiological evidence of allergic disorders and cancer occurrence, 52–56
 - mast cells in, 145
 - Lymphocytic leukemias, 83
 - potential mechanistic interactions between allergy/atopy associated with hematopoietic cancers development, 122
 - See also* Myelogenous leukemias

- Lymphoid malignancy associations, atopy and, 122
- Lymphoma
 Hodgkin lymphoma (HL), 112–113
 mast cells in, 145
 non-Hodgkin lymphoma (NHL), 96–112
- M**
- Macrophages
 alternatively activated (Th2-mediated anti-tumor immunity), 264–265
 IgE effector cells in cancer and, 191–192
- Mast cells (MCs), 137
 as APCs, 141–142
 in allergy
 airway tissue remodeling and, 142–143
 MCs and dendritic cells, 139–141
 MCs and T cells and, 141–142
 MCs subsets, 138–139
 in cancer, 143
 adaptive immune responses to tumors, regulation of, 148, 150
 angiogenesis, 143–144
 human tumors, 145–147
 IgE-mediated effector cell responses, 190, 203–204
 tumor growth or rejection (MC mediators), 145, 148
 subsets
 connective tissue (CTMC), 138–139
 mucosal (MMC), 138–139
 Th2-mediated and anti-tumor immunity, 266–267
- Melanoma, 68
See also Atopic dermatitis
- Membrane form mRNA, 24–26
- Membrane IgE (mIgE)
 antigen receptor function and in vivo IgE synthesis and, 22–24
 structural features
 cytoplasmic domain, 22
 EMPD, 22
 transmembrane domain, 22
 transcript generation restriction by impaired splicing and polyadenylation, 24, 26
See also B cell receptor (BCR)
- Meningioma
 epidemiological evidence of allergic disorders and cancer occurrence, 60–62
See also Glioma
- Migratory plasmablasts, 26
 chemokine ligand (CXCL) and receptors (CXCR), 27
See also IgE
- Mimotopes, 232
 vaccination, 175–176
See also IgE in cancer therapy; Paratopes
- Modified vaccinia virus Ankara (MVA)
 as cell killing agents coupled to IgE loading in mice, 220–221
 as resource for human therapy and recombinant protein expression, 221–222
 mouse membrane-bound IgE implementation by recombinant MVA, 224–225
See also Vaccinia virus (VV)
- Monocytes, IgE effector cells in cancer and, 191–192
- Mouse IgE
 tumor growth and improved mice survival, 216
 cell types involved in IgE-induced tumor protection, 217–218
 FcεRI humanized mice and human IgE in tumor vaccination, 225–226
 IgE adjuvant effect (tumor vaccination), 218–219
 IgE-FcεRI adjuvanticity in tumor vaccination, 223–224
 mouse membrane-bound IgE implementation by recombinant MVA, 224–225
 MVA as resource for human therapy and recombinant protein expression, 221–222
 transgenic mice use for IgE receptor involvement and human IgE implementation, 222
 Vaccinia virus and MVA as cell killing agents coupled to IgE loading, 220–221
See also IgE in cancer therapy
- Mouse mammary tumor virus (MMTV), 168–169
- MOv18
 IgE-mediated tumor responses
 anti-tumoral responses, 195
 chimeric ovarian carcinoma, 195
 IgE-mediated tumor killing mechanisms
 ADCC, 197, 199
 ADCP, 199–202
See also Effector cell responses; Trastuzumab like IgE

mRNA

Ig mRNA processing

IgA, 25

IgE, 26

IgG, 25

IgM, 25

membrane form, 24–26

secreted form, 24–26

See also IgE

Mucosal mast cells (MMC), 138–139

See also Connective tissue mast cells (CTMC)

Multiple myeloma, 116

allergic disorders and hematopoietic malignancies (epidemiological evidence), 116–122

mast cells in, 145

See also Plasmacytoma

Murine

IgE

rat IgE specific for murine CD8, 169–170

specific for antigenic determinant on colorectal carcinoma cells surface, 170–171

specific for gp36 of MMTV, 168–169

specific for human folate binding protein, 171–173

See also Mouse IgE

Murine monoclonal antibodies (mAbs), 18–20

Myelogenous leukemias, 83

See also Lymphocytic leukemiasMyeloma, *see* Multiple myeloma

N

Natural IgE antibodies, 37

See also Low-affinity IgE antibodies

Natural killer (NK) cells

IgE cancer therapy and, 165

IgE effector cells in cancer and, 193

Negative feedback function (CD23), 20–22

Nervous system tumors

epidemiological evidence of allergic disorders and cancer occurrence, 60, 62–64

See also Acoustic neuroma; Brain tumors; Neuroblastoma

Neuroblastoma

epidemiological evidence of allergic disorders and cancer occurrence, 64

See also Acoustic neuroma

Non-Hodgkin lymphoma (NHL)

allergic disorders and epidemiological evidence of, 96–112

case control studies, 98–112

hematopoietic malignancies, 122

chimeric IgE targeting human CD20 and, 174–175

See also Hodgkin lymphoma (NHL)

O

Omalizumab

cancer therapy and, 162–163

See also IgE in cancer therapy

Ovarian cancer

antigen-specific MOv18 in IgE-mediated anti-tumoral responses, 195

epidemiological evidence of allergic disorders and cancer occurrence, 65–66

P

Pancreatic cancer

epidemiological evidence of allergic disorders and cancer occurrence, 56–60

IgE-mediated anti-tumor responses, 205

Paratopes

crosslinking (antigens) and, 232

See also Mimotopes

Pathogen-associated molecular patterns (PAMPs), 238

See also Allergen-associated molecular patterns (AAMP); Tumor-associated molecular patterns

Peripheral blood mononuclear cells (PBMC)

in IgE-mediated anti-tumoral responses, 194

See also Effector cell responsesPirquet's allergy, *see under* Allergy

Plasma, 26

Plasma cell malignancies

allergic disorders and epidemiological evidence of, 113, 116–122

multiple myeloma, 116

plasmacytoma, 116

See also Cancers

Plasmablasts

IgE plasmablasts contribution to long-lived plasma cell pool, 26–27

migratory, 26–27

See also Humoral immunological memory

Plasmacytoma, 116

See also Multiple myeloma

- Polyadenylation
 cleavage-polyadenylation specificity factor (CPSF), 25
 external, 26
 impaired splicing and polyadenylation restricting mature mIgE transcript generation, 24–26
 internal, 24
See also Epsilon-HC gene
- Prostate cancer
 epidemiological evidence of allergic disorders and cancer occurrence, 65–66
See also Reproductive cancers
- R**
- Reagin antibodies, 4
 and local anti-tumor anaphylaxis, 166–167
See also IgE in cancer therapy
- Recombination, *see* Class switch recombination (CSR)
- Replication protein A (RPA), 18
- Reproductive cancers
 epidemiological evidence of allergic disorders and cancer occurrence, 65–66
See also Cancers; Anti-tumor
- S**
- Secreted form mRNA, 24–26
- Sequential switching
 high-affinity IgE antibodies generation (experimental evidence)
 IgG1⁺ B cells generating IgE antibodies by sequential switching, 43
 interleukin-21 inhibiting sequential switching of IgG1⁺ cells to IgE, 43–44
See also Class switch recombination (CSR)
- Serum immunoglobulins
 half life, 18–20
 serum IgE, 18–20
 serum IgG, 19–20
- Skin cancer, 68
 epidemiological evidence of allergic disorders and cancer occurrence, 68
 melanoma, 68
 nonmelanoma, 68
- Smokers
 allergy lung cancer in non-smokers, 54
 esophageal cancer and cigarette, 67
See also AllergoOncology (epidemiological evidence of allergic disorders and cancer occurrence); Asthma
- Somatic hypermutation, 37
 high-affinity IgE antibodies generation, 42–43
See also Affinity maturation
- Splicing
 impaired splicing and polyadenylation restricting mature mIgE transcript generation, 24–26
See also Polyadenylation
- Stomach cancer, 67
- Switching
 high-affinity IgE antibodies generation aspects (sequential switching to IgE in mice and humans), 40
 low-affinity IgE antibodies generation aspects
 class switching, 39
 direct switching from IgM to IgE, 38
- T**
- T cell interactions
 mast cells and, 141–142
 Th2-mediated and anti-tumor immunity
 CD4⁺ T cells (Th1 and Th2 paradigm in tumor biology), 256–257
 CD8⁺ T cells (Tc2 cells), 267–268
- T–B cell interactions, 37–38
 IgE⁺ cells found outside GC in both T/B monoclonal mice (T-Bmc) and wild-type mice, 42
See also High-affinity IgE antibodies
- Tc2 cells (Th2-mediated and anti-tumor immunity), 267–268
- Testicular cancer, 65
- Th17 cells
 and B-cell NHL (IgE-mediated allergies), 126–128
See also Cancers
- Th2-mediated anti-tumor immunity, 255
 alternatively activated macrophages, 264–265
 B cells, 266
 CD4⁺ T cells (Th1 and Th2 paradigm), 256–257
 eosinophils and eosinophil-derived mediators, 262–264
 IgE, 265–266
 IgG, 265–266

mast cells and mast-cell mediators,
 266–267
 Tc2 cells, 267–268
 Th2 cytokines, 257
 IL-13, 258, 260
 IL-24, 258, 261
 IL-25, 258, 261–262
 IL-4, 257–260
 Transmembrane domain, 22
 Trastuzumab, 175
 Trastuzumab like IgE, 202–203
 IgE-mediated tumor killing mechanisms
 (ADCP), 202
 See also Effector cell responses; MOv18
 Tumor allergy, 4
 mechanism, 6
 See also AllergoOncology; Cancers
 Tumor-associated macrophages (TAMs),
 191–192, 264
 Tumor-associated molecular patterns, 242
 See also Allergen-associated molecular
 patterns (AAMP);
 Pathogen-associated molecular
 patterns (PAMPs)

U

Urothelial cancer, 67
 Uterine cancer
 epidemiological evidence of allergic
 disorders and cancer occurrence,
 65–66
 See also Reproductive cancers

V

Vaccination
 endogenous IgE response via mimotope
 vaccination,
 175–176
 See also IgE adjuvant effect (tumor
 vaccination); IgE in cancer
 therapy
 Vaccinia virus (VV)
 as cell killing agents coupled to IgE loading
 in mice, 220–221
 See also Modified vaccinia virus Ankara
 (MVA)